Brain Ischemia and Reperfusion: Cellular and Molecular Mechanisms in Stroke Injury

Basic Neurochemistry

Volumn , Issue , 2012, Pages 621-642

  Belayev, Ludmila ^a   Lu, Youming ^a   Bazan, Nicolas G ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868149276     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374947-5.00035-3     Document Type: Chapter

References (98)

1. Aarts M., Liu Y., Liu L., et al. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science 2002, 298:846-850.
2. Agre P., King L.S., Yasui M., et al. Aquaporin water channels-from atomic structure to clinical medicine. Journal of Physiology 2002, 542:3-16.
3. Aktan A.O., Yalcin A.S. Ischemia-reperfusion injury, reactive oxygen metabolites, and the surgeon. Turkish Journal of Medical Sciences 1998, 28:1-5.
4. Allen C.L., Bayraktutan U. Oxidative stress and its role in the pathogenesis of ischaemic stroke. International Journal of Stroke 2009, 4:461-470.
5. 2+ exchanger in excitotoxicity. Cell 2005, 120:275-285.
6. Bazan N.G. Neuroprotectin D1 (NPD1): A DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathology 2005, 15:159-166.
7. Bazan N.G. Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease. Journal of Lipid Research 2009, 50:S400-S405.
8. Belayev L., Busto R., Zhao W., et al. Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Research 1996, 739:88-96.
9. Belayev L., Khoutorova L., Atkins K.D., et al. Robust docosahexaenoic acid-mediated neuroprotection in a rat model of transient, focal cerebral ischemia. Stroke 2009, 40:3121-3126.
10. Belayev L., Khoutorova L., Atkins K.D., et al. Docosahexaenoic acid therapy of experimental ischemic stroke. Translational Stroke Research 2011, March, (In press).
11. Belayev L., Liu Y., Zhao W., et al. Human albumin therapy of acute ischemic stroke: Marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001, 32:553-560.
12. Belayev L., Marcheselli V.L., Khoutorova L., et al. Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Stroke 2005, 36:118-123.
13. Belayev L., Pinard E., Nallet H., et al. Albumin therapy of transient focal cerebral ischemia: In vivo analysis of dynamic microvascular responses. Stroke 2002, 33:1077-1084.
14. Belayev L., Saul I., Huh P.W., et al. Neuroprotective effect of high-dose albumin therapy against global ischemic brain injury in rats. Brain Research 1999, 845:107-111.
15. Borsello T., Clarke P.G., Hirt L., et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nature Medicine 2003, 9:1180-1186.
16. Clark W.M. Efficacy of citicoline as an acute stroke treatment. Expert Opinion on Pharmacotherapy 2009, 10:839-846.
17. Connolly E.S., Winfree C.J., Springer T.A., et al. Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. Journal of Clinical Investigation 1996, 97:209-216.
18. Dankbaar J.W., Hom J., Schneider T., et al. Dynamic perfusion-CT assessment of early changes in blood-brain barrier permeability of acute ischaemic stroke patients. Journal of Neuroradiology 2010.
19. de Groot H., Rauen U. Ischemia-reperfusion injury: Processes in pathogenetic networks: A review. Transplantation Proceedings 2007, 39:481-484.
20. del Zoppo G.J. Stroke and neurovascular protection. The New England Journal of Medicine 2006, 354:553-555.
21. del Zoppo G.J., Schmid-Schönbein G.W., Mori E., et al. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 1991, 22:1276-1283.
22. Dobbin J., Crockard H.A., Ross-Russell R. Transient blood-brain barrier permeability following profound temporary global ischaemia: An experimental study using 14C-AIB. Journal of Cerebral Blood Flow and Metabolism 1989, 9:71-78.
23. Ebinger M., De Silva D.A., Christensen S., et al. Imaging the penumbra-strategies to detect tissue at risk after ischemic stroke. Journal of Clinical Neuroscience 2009, 16:178-187.
24. Imaging the penumbra-strategies to detect tissue at risk after ischemic stroke. Journal of Clinical Neuroscience 2009, 16: 178-187.
25. Faulkner J.R., Herrmann J.E., Woo M.J., et al. Reactive astrocytes protect tissue and preserve function after spinal cord injury. The Journal of Neuroscience 2004, 24:2143-2155.
26. Fisher M. The ischemic penumbra: A new opportunity for neuroprotection. Cerebrovascular Diseases 2006, 2:64-70.
27. Fisher M. New approaches to neuroprotective drug development. Stroke 2011, 42:S24-S27.
28. Fiskum G., Murphy A.N., Beal M.F. Mitochondria in neurodegeneration: Acute ischemia and chronic neurodegenerative diseases. Journal of Cerebral Blood Flow and Metabolism 1999, 19:351-369.
29. Ginsberg M.D., Palesch Y.Y., Martin R.H., et al. The albumin in acute stroke (ALIAS) multicenter clinical trial: Safety analysis of part 1 and rationale and design of part 2. Stroke 2011, 42:119-127.
30. Grotta J. and combination therapy stroke trial investigators. combination therapy stroke trial: Recombinant tissue-type plasminogen activator with/without lubeluzole. Cerebrovascular Diseases 2001, 12:258-263.
31. + channels. Annual Review of Physiology 1997, 59:23-42.
32. Hall A.A., Pennypacker K.R. Implications of immune system in stroke for novel therapeutic approaches. Translational Stroke Research 2010, 1:85-95.
33. Hall E.D., Andrus P.K., Smith S.L., et al. Neuroprotective efficacy of microvascularly localized versus brain-penetrating antioxidants. Acta Neurologica Supplementum 1996, 66:107-113.
34. Halliwell B. Reactive oxygen species and the central nervous system. Journal of Neurochemistry 1992, 59:1609-1623.
35. Hardingham G.E., Bading H. Synaptic versus extra-synaptic NMDA receptor signaling: Implications for neurodegenerative disorders. Nature Reviews Neuroscience 2010, 11:682-696.
36. Heiss W.D. The concept of the penumbra: Can it be translated to stroke management?. International Journal of Stroke 2010, 5:290-295.
37. Hossmann K.M.A. Pathophysiological basis of translational stroke research. Folia Neuropathologica 2009, 47:213-227.
38. Jin R., Yang G., Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: Critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiology of Disease 2010, 38:376-385.
39. Kleindorfer D., Kissela B., Schneider A., et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: A population-based study. Stroke 2004, 35:27-29.
40. Kloska S.P., Wintermark M., Engelhorn T., et al. Acute stroke magnetic resonance imaging: Current status and future perspective. Neuroradiology 2010, 52:189-201.
41. Kristian T., Siesjo B.K. Changes in ionic fluxes during cerebral ischaemia. International Review of Neurobiology 1997, 40:27-45.
42. 2+-dependent inactivation of NMDA receptors. Journal of Neuroscience 1999, 19:1165-1178.
43. Lee J.K., Kwak H.J., Piao M.S., et al. Quercetin reduces the elevated matrix metalloproteinases-9 level and improves functional outcome after cerebral focal ischemia in rats. Acta Neurologica 2010.
44. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. Nature Reviews Discovery 2006, 5:160-170.
45. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:e21-e181.
46. Lo E.H., Broderick J.P., Moskowitz M.A. tPA and proteolysis in the neurovascular unit. Stroke 2004, 35:354-356.
47. Lo E.H., Dalkara T., Moskowitz M.A. Mechanisms, challenges and opportunities in stroke. Nature Reviews Neuroscience 2003, 4:399-415.
48. Lucas S.M., Rothwell N.J., Gibson R.M. The role of inflammation in CNS injury and disease. British Journal of Pharmacology 2006, 147(Suppl. 1):s232-s240.
49. Lukiw W.J., Cui J.G., Marcheselli V.L., et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. Journal of Clinical Investigation 2005, 115:2774-2783.
50. Lyden P., Jacoby M., Schim J., et al. The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): Final results. Neurology 2001, 57:1199-1205.
51. Ma J., Qiu J., Hirt L., et al. Synergistic protective effect of caspase inhibitors and bFGF against brain injury induced by transient focal ischaemia. British Journal of Pharmacology 2001, 133:345-350.
52. Marcheselli V.L., Hong S., Lukiw W.J., et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. The Journal of Biological Chemistry 2003, 278:43807-43817.
53. Markus R., Reutens D.C., Kazui S., et al. Hypoxic tissue in ischaemic stroke: Persistence and clinical consequences of spontaneous survival. Brain 2004, 127:1427-1436.
54. Mehta S.L., Manhas N., Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Research Reviews 2007, 54:34-66.
55. Minnerup J., Heidrich J., Wellmann J., et al. Meta-analysis of the efficacy of granulocyte-colony stimulating factor in animal models of focal cerebral ischemia. Stroke 2008, 39:1855-1861.
56. Molina C.A. Reperfusion therapies for acute ischemic stroke: Current pharmacological and mechanical approaches. Stroke 2011, 42:S16-S19.
57. Moskowitz M.A., Lo E.H., Iadecola C. The science of stroke: Mechanisms in search of treatments. Neuron 2010, 67:181-198.
58. Nakka V.P., Gusain A., Mehta S.L., et al. Molecular mechanisms of apoptosis in cerebral ischemia: Multiple neuroprotective opportunities. Molecular Neurobiology 2008, 37:7-38.
59. Nicholls D., Attwell D. The release and uptake of excitatory amino acids. Trends in Pharmacological Sciences 1990, 11:462-468.
60. Oku N., Kashiwagi T., Hatazawa J., et al. Nuclear neuroimaging in acute and subacute ischemic stroke. Annals of Nuclear Medicine 2010, 24:629-638.
61. Palesch Y.Y., Hill M.D., Ryckborst K.J., et al. The ALIAS Pilot Trial: A dose-escalation and safety study of albumin therapy for acute ischemic stroke-II: Neurologic outcome and efficacy analysis. Stroke 2006, 37.
62. Pan J., Konstas A.A., Bateman B., et al. Reperfusion injury following cerebral ischemia: Pathophysiology, MR imaging, and potential therapies. Neuroradiology 2007, 49:93-102.
63. Pulsinelli W. Pathophysiology of acute ischaemic stroke. Lancet 1992, 339:533-536.
64. Ramos-Cabrer P., Campos F., Sobrino T., et al. Targeting the Ischemic Penumbra. Stroke 2011, 42:7-11.
65. Ramos-Fernandez M., Bellolio M.F., Stead L.G. Matrix metalloproteinase-9 as a marker for acute ischemic stroke: A systematic review. Journal of Stroke and Cerebrovascular Diseases 2011, 20:47-54.
66. Ringelstein E.B., Nabavi D.G. Cerebral small vessel diseases: Cerebral microangiopathies. Current Opinion in Neurology 2005, 18:179-188.
67. Rivers C.S., Wardlaw J.M., Armitage P.A., et al. Do acute diffusion- and perfusion-weighted MRI lesions identify final infarct volume in ischemic stroke?. Stroke 2006, 37:98-104.
68. Rodriguez de Turco E.B., Belayev L., Liu Y., et al. Systemic fatty acid responses to transient focal cerebral ischemia: Influence of neuroprotectant therapy with human albumin. Journal of Neurochemistry 2002, 83:515-524.
69. Rogalewski A., Schneider A., Ringelstein E.B., et al. Toward a multimodal neuroprotective treatment of stroke. Stroke 2006, 37:1129-1136.
70. Rothwell N.J., Luheshi G.N. Interleukin 1 in the brain: Biology, pathology and therapeutic target. Trends in Neurosciences 2000, 23:618-625.
71. Sage J.I., Van Uitert R.L., Duffy T.E. Early changes in blood brain barrier permeability to small molecules after transient cerebral ischemia. Stroke 1984, 15:46-50.
72. Sandoval K.E., Witt K.A. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiology of Disease 2008, 32:200-219.
73. Schäbitz W.R., Li F., Irie K., et al. Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia. Stroke 1999, 30:42731.
74. Schmid-Elsaesser R., Hungerhuber E., Zausinger S., et al. Neuroprotective efficacy of combination therapy with two different antioxidants in rats subjected to transient focal ischemia. Brain Research 1999, 816:471-479.
75. Schreiber J., Eling T.E., Mason R.P. The oxidation of arachidonic acid by the cyclooxygenase activity of purified prostaglandin H synthase: Spin trapping of a carbon- centered free radical intermediate. Archives of Biochemistry and Biophysics 1986, 249:126-136.
76. Serhan C.N., Yacoubian S., Yang R. Anti-inflammatory and proresolving lipid mediators. Annual Review of Pathology 2008, 3:279-312.
77. Sheng H., Bart R.D., Oury T.D., et al. Mice overexpressing extracellular superoxide dismutase have increased resistance to focal cerebral ischemia. Neuroscience 1999, 88:185-191.
78. Simard J.M., Sahuquillo J., Sheth K.N., et al. Managing malignant cerebral infarction. Current Treatment Options in Neurology 2010.
79. Simon R.P., Swan J.H., Meldrum B.S. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 1984, 226:850-852.
80. Simopoulos A.P. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Experimental Biology and Medicine (Maywood) 2008, 233:674-688.
81. Singhal A., Lo E., Dalkara T., et al. Ischemic Stroke: Basic Pathophysiology and Neuroprotective Strategies. Acute ischemic stroke. Part 1 2006, Springer-Verlag Berlin Heidelberg, New York.
82. Smith W.S. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR American Journal of Neuroradiology 2006, 27:1177-1182.
83. Sugawara T., Chan P.H. Reactive oxygen radicals and pathogenesis of neuronal death after cerebral ischemia. Antioxidants & Redox Signaling 2003, 5:597-607.
84. Thomas C.G., Miller A.J., Westbrook G.L. Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. Journal of Neurophysiology 2006, 95:1727-1734.
85. Trotti D., Rizzini B.L., Rossi D., et al. Neuronal and glial glutamate transporters possess an SH-based redox regulatory mechanism. The European Journal of Neuroscience 1997, 9:1236-1243.
86. Tu W., Xu X., Peng L., et al. DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. Cell 2010, 140:222-234.
87. Van Eldik L.J. Structure and enzymology of a death-associated protein kinase. Trends in Pharmacological Sciences 2002, 23:302-304.
88. Wang J., Liu S.H., Fu Y.P., et al. Cdk5 activation induces CA1 pyramidal cell death by direct phosphorylation of NMDA receptors. Nature Neuroscience 2003, 6:1039-1047.
89. Ward R.E., Huang W., Curran O.E., et al. Docosahexaenoic acid prevents white matter damage after spinal cord injury. Journal of Neurotrauma 2010, 27:1769-1780.
90. Weiss N., Miller F., Cazaubon S., et al. The blood-brain barrier in brain homeostasis and neurological diseases. Biochimica et Biophysica Acta 2009, 1788:842-857.
91. Primer on cerebrovascular diseases 1997, Academic Press, San Diego, CA. K.M.A. Welch, L.R. Caplan, D.J. Reis, B.K. Siesjo, B. Weir (Eds.).
92. White B.C., Sullivan J.M., DeGracia D.J., et al. Brain ischemia and reperfusion: Molecular mechanisms of neuronal injury. Journal of Neurological Sciences 2000, 179:1-33.
93. Xiong Z.G., Zhu X.M., Chu X.P., Minami M., Hey J., Wei W.L., et al. Neuroprotection in ischemia: Blocking calcium-permeable acid-sensing ion channels. Cell 2004, 118:687-698.
94. Yamashita T., Deguchi K., Nagotani S., et al. Vascular protection and restorative therapy in ischemic stroke. Cell Transplant 2010.
95. Zador Z., Stiver S., Wang V., et al. Role of aquaporin-4 in cerebral edema and stroke. Handbook of Experimental Pharmacology 2009, 190:159-170.
96. Zhang L., Zhang Z.G., Liu X., et al. Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator. Thrombosis and Haemostasis 2006, 95:166-173.
97. Zhang R.L., Chopp M., Chen H., et al. Temporal profile of ischemic tissue damage, neutrophil response, and vascular plugging following permanent and transient (2H) middle cerebral artery occlusion in the rat. Journal of Neurological Sciences 1994, 125:3-10.
98. Zou Y., Chen C.H., Fike J.R., et al. A new mouse model for temporal- and tissue-specific control of extracellular superoxide dismutase. Genesis 2009, 47:142-154.